Back to Search
PETER LINDGREN, MD
MD
Pediatrics Physician
NPI: 1255370961Individual
Specialties, Licenses & Credentials
Pediatrics PhysicianPrimary
Pediatrics
Code: 208000000X
3485661205(UT)
Research & Publications (20)
Utility loss and indirect costs after stroke in Sweden.
PMID 18391653·Eur J Cardiovasc Prev Rehabil·2008
4-observational
Lifestyle intervention to prevent diabetes in men and women with impaired glucose tolerance is cost-effective.
PMID 17493303·Int J Technol Assess Health Care·2007
8-other
Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
PMID 15703503·Eur J Cardiovasc Prev Rehabil·2005
3-trial
The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
PMID 15763611·Clin Ther·2005
8-other
Cost-effectiveness of clopidogrel in acute coronary syndromes in Sweden: a long-term model based on the CURE trial.
PMID 15078498·J Intern Med·2004
3-trial
Cost-effectiveness of primary prevention of coronary heart disease through risk factor intervention in 60-year-old men from the county of Stockholm--a stochastic model of exercise and dietary advice.
PMID 12649048·Prev Med·2003
3-trial
The impact of acute myocardial infarction and stroke on health care costs in patients with type 2 diabetes in Sweden.
PMID 19491686·Eur J Cardiovasc Prev Rehabil·2009
8-other
Bridging science and health policy in cardiovascular disease: focus on lipid management: A Report from a Session held during the 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases: Prevention and Intervention--Health Policy, in Venice, Italy, on 25 October, 2008.
PMID 19497553·Atheroscler Suppl·2009
8-other
An economic evaluation of NIOX MINO airway inflammation monitor in the United Kingdom.
PMID 19183419·Allergy·2009
8-other
Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
PMID 19508663·Value Health·2009
4-observational
From 4S to IDEAL: the health economics of the statin trials.
PMID 19378393·Eur J Cardiovasc Prev Rehabil·2009
6-review
Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
PMID 19331709·Int J Technol Assess Health Care·2009
8-other
The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
PMID 19354342·Pharmacoeconomics·2009
4-observational
Quantification of genes encoding resistance to aminoglycosides, beta-lactams and tetracyclines in wastewater environments by real-time PCR.
PMID 19370439·Int J Environ Health Res·2009
8-other
Activity and composition of ammonia oxidizing bacterial communities and emission dynamics of NH3 and N2O in a compost reactor treating organic household waste.
PMID 19210570·J Appl Microbiol·2009
8-other
Preservation of biological markers in clasts within impact melt breccias from the Haughton impact structure, Devon Island.
PMID 19519214·Astrobiology·2009
8-other
Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS).
PMID 19570117·Int J Clin Pract·2009
4-observational
The long-term cost of multiple sclerosis in France and potential changes with disease-modifying interventions.
PMID 19383645·Mult Scler·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2000 S 900 E
SALT LAKE CITY, UT 84105 - Phone
- (801) 464-7600
Quick Facts
- NPI
- 1255370961
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile